← Oncology Approval Tracker

FDA DECISION ·

Xeloda + combination treatment

capecitabine within a combination regimen · Genentech

FDA approvalNew or expanded indicationGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Part of a combination regimen for adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma without prior metastatic treatment.

LAMPGEN ANALYSIS

Why it matters

This indication specifies a HER2-defined first-line metastatic population.

What research teams should watch

Verify the HER2 result and prior treatment setting and document the HER2-directed regimen component.

PRIMARY RECORDS

Sources